Good news for Cell Thera as FDA clears Italian pixantrone production facility

10 March 2010

There was good news for USA-based Cell Therapeutics yesterday, in that that the Food and Drug Administration has completed its inspection of the company's manufacturing facility in in Nerviano, Italy, that is owned by Nerviano Medical Sciences, and found it to be compliant with all the required norms.

Cell Therapeutics' shares, which slumped early last month after the FDA questioned the safety and effectiveness of the drug, jumped 25% to $1.12 in morning trading yesterday.

The production site makes Cell Therapeutics' Pixuvri (pixantrone), which is currently under FDA review for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL) in patients who have not responded to other treatment options. A final decision on the drug should be taken by April 23.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >